Company news from the 09/12/06 News Brief

Share this article:
MedImmune broke ground on a $250 million, multi-phase expansion project at its Frederick, MD, manufacturing site. The expansion will increase MedImmune's manufacturing capacity for monoclonal antibodies including Synagis, which it introduced to the market in 1998 and other products in the company's pipeline.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.